cephalosporin c has been researched along with Skin Diseases, Bacterial in 112 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (13.39) | 18.2507 |
| 2000's | 25 (22.32) | 29.6817 |
| 2010's | 67 (59.82) | 24.3611 |
| 2020's | 5 (4.46) | 2.80 |
| Authors | Studies |
|---|---|
| Claeys, KC; Davis, SL; Delaportes, DJ; Estrada, SJ; Huang, V; Jorgensen, SCJ; Kaye, KS; Klinker, KP; Lagnf, AM; Rybak, MJ; Trinh, TD; Zasowski, EJ | 1 |
| Flamm, RK; Pfaller, MA; Shortridge, D; Streit, JM | 1 |
| Buonomo, AR; Congera, P; Foggia, M; Gentile, I; Maraolo, AE; Parente, S; Scotto, R; Zappulo, E | 1 |
| Hsueh, PR; Jean, SS; Ko, WC | 1 |
| Engelhardt, M; Gonzalez-Rojas, Y; Gumenchuk, I; Hamed, KA; Ionescu, D; Jones, ME; Keech, R; Kim, C; Ninov, B; Overcash, JS; Saulay, M; Simeonov, S; Smart, JI; Waters, M | 1 |
| Engelhardt, M; Hamed, K; Overcash, JS; Saulay, M; Scheeren, TW; Welte, T | 1 |
| Castanheira, M; Flamm, RK; Jones, RN; Mendes, RE; Pfaller, MA; Sader, HS | 1 |
| Bassetti, M; Castaldo, N; Givone, F; Peghin, M; Righi, E; Sartor, A | 1 |
| Cho, YL; Kim, HS; Kwak, JH; Oh, K; Oh, SH; Park, HS; Yun, JY | 1 |
| Arcenillas, P; Boix-Palop, L; Calbo, E; Cuchi, E; Dietl, B; Gómez, L; González de Molina, FJ; Nicolás, J; Sánchez, I | 1 |
| Artioli, S; Bassetti, M; Capone, A; Carannante, N; Castaldo, N; Cattelan, A; Cipriani, L; Coletto, D; Digaetano, M; Grossi, P; Losito, AR; Mastroianni, CM; Menichetti, F; Mussini, C; Nicolè, S; Peghin, M; Righi, E; Russo, A; Tascini, C; Tumbarello, M; Vena, A | 1 |
| Corey, GR; Das, S; Dryden, M; Friedland, HD; Gonzalez, J; Iaconis, J; Jandourek, A; Wilcox, MH; Wilson, DJ | 1 |
| Barberán, J | 1 |
| Farrell, DJ; Flamm, RK; Jones, RN; Sader, HS | 3 |
| Flamm, RK; Jones, RN; Sader, HS | 1 |
| Beresford, E; Friedland, HD; Huang, X; Lodise, T | 1 |
| Ambrose, PG; Bhavnani, SM; Forrest, A; Khariton, T; Reynolds, DK; Riccobene, T; Rubino, CM; Van Wart, SA | 1 |
| David Friedland, H; Davis, A; Jandourek, A; Santos, PD; Smith, A | 1 |
| Flamm, RK; Jones, RN; Pfaller, MA; Sader, HS | 1 |
| Beresford, E; Biek, D; Friedland, HD; Jandourek, A; Mawal, Y; Riccobene, T | 1 |
| Barber, KE; Barr, VO; Casapao, AM; Davis, SL; Goff, DA; Kaye, KS; Klinker, KP; Molloy, LM; Mynatt, RP; Pogue, JM; Rybak, MJ | 1 |
| Hata, Y; Iketani, Y; Oguri, T; Yamamoto, N | 1 |
| Barberán, J; Cisneros, JM | 1 |
| Holmes, NE; Howden, BP | 1 |
| Farrell, DJ; Flamm, RK; Jones, RN; Mendes, RE; Sader, HS | 1 |
| Cole, P; Evans, J; Friedland, HD; Udeani, G | 1 |
| Cole, P; Evans, JD; Friedland, HD; Udeani, G | 1 |
| Eckmann, C | 2 |
| Cole, P; Friedland, HD; Maggiore, C; Pasquale, T | 1 |
| Canut, A; Isla, A; Rodríguez-Gascón, A | 1 |
| Castanheira, M; Farrell, DJ; Flamm, RK; Jones, RN; Mendes, RE; Sader, HS | 1 |
| Cole, P; Friedland, HD; Guervil, DJ; Hassoun, A; Huang, XY; Kaye, KS | 1 |
| Cates, JE; Li, G; Mitrani-Gold, FS; Mundy, LM | 1 |
| Ahmed, S; Ali, SA; Arsalan, A; Naqvi, SB; Shakeel, O | 1 |
| James, D; Kearns, A; Livermore, DM; Mushtaq, S; Warner, M; Woodford, N | 1 |
| Biedenbach, DJ; Bouchillon, SK; Iaconis, JP; Karlowsky, JA; Reiszner, E; Sahm, DF | 1 |
| Antadze, T; Bradley, JS; Giorgobiani, M; Jandourek, A; Korczowski, B; O'Neal, T; Smith, A; Stryjewski, ME | 1 |
| Biedenbach, DJ; Bouchillon, SK; Hackel, M; Iaconis, JP; Karlowsky, JA; Sahm, DF | 1 |
| Bradley, JS; Carrothers, TJ; Das, S; Jandourek, A; Khariton, T; Knebel, W; Li, J; Riccobene, TA | 1 |
| Dryden, M; Gonzalez, J; Iaconis, JP; Wilson, D; Zhang, Y | 1 |
| Crespo Casal, M; Martinez-Lamas, L; Nodar, A; Perez-Landeiro, A; Perez-Rodríguez, MT; Sousa Dominguez, A | 1 |
| Arber, M; Barata, T; Eales, J; Fleetwood, K; Glanville, J; Gould, IM; Kauf, TL; McCool, R | 1 |
| Amsler, KM; Bush, K; Davies, TA; Jacobs, MR; Shang, W | 1 |
| Cohen, R; Raymond, J | 1 |
| Cohen, R; Gillet, Y; Moulin, F; Quinet, B; Raymond, J | 1 |
| Corey, GR; Kanafani, ZA | 1 |
| Biedenbach, DJ; Jones, RN | 1 |
| Cabeza, J; Carrasco, C; Gutierrez, J; Sorlozano, A; Villegas, E | 1 |
| Deresinski, SC; Schirmer, PL | 1 |
| Corey, GR; Nannini, EC; Stryjewski, ME | 1 |
| Cooper, C; Kim, PW; Kornegay, C; Nambiar, S; Rochester, G; Valappil, T; Wang, Y; Wu, YT | 1 |
| Baculik, T; Corey, GR; Critchley, I; Das, AF; Friedland, HD; Talbot, GH; Thye, D; Wilcox, M; Witherell, GW | 1 |
| Jones, RN; Mendes, RE; Sader, HS | 1 |
| Moellering, RC | 1 |
| Drusano, GL | 2 |
| Baculik, T; Corey, GR; Friedland, D; Talbot, GH; Thye, D; Wilcox, MH | 2 |
| Corrado, ML | 1 |
| Biek, D; Critchley, IA; Riccobene, TA; Thye, DA | 1 |
| Kanafani, ZA | 1 |
| Kelly, N; Papp, R; Popovic, A; Tschirret-Guth, R | 1 |
| Jain, A; Kaushik, D; Rathi, S | 1 |
| Kalil, AC | 1 |
| Laudano, JB | 1 |
| Belavic, JM | 1 |
| Carver, PL; DePestel, DD; Jorgenson, MR | 1 |
| Wilcox, MH | 1 |
| Biek, D; Eckburg, PB; Friedland, HD; Laudano, JB; Llorens, L; O'Neal, T; Rank, DR; Smith, A; Thye, D; Witherell, GW | 1 |
| Nikitin, AV | 1 |
| Casapao, AM; Levine, DP; Rybak, MJ; Steed, ME | 1 |
| Lodise, TP; Low, DE | 1 |
| Leakey, A; Morrissey, I; Northwood, JB | 1 |
| Barriere, SL; Churukian, A; Corey, GR; Kingsley, J; Li, YP; Potgieter, PD; Stryjewski, ME | 1 |
| Coutinho, AS; de Morais, OO; de Oliveira Carneiro da Motta, J; Gomes, CM | 1 |
| Balbisi, EA | 1 |
| Devcich, KJ; París, MM | 1 |
| Fritsche, TR; Jones, RN; Sader, HS; Streit, JM | 1 |
| Jones, RN; Sader, HS | 1 |
| Del Rosso, J | 1 |
| Hedrick, J | 1 |
| Akinlade, BK; Busman, TA; Cifaldi, M; Elston, D; Giordano, PA; Nilius, AM; Notario, GF; Weber, K | 1 |
| Noel, GJ | 1 |
| Amsler, K; Heep, M; Noel, GJ; Pypstra, R; Solomkin, JS; Strauss, RS | 1 |
| Bagchi, P; Bush, K; Ianus, J; Noel, GJ; Strauss, RS | 1 |
| Fritsche, TR; Gorodecky, E; Jones, RN; Lodise, TP; Patel, N; Renaud-Mutart, A | 1 |
| Deresinski, SC | 1 |
| Nolen, T | 1 |
| Azuma, E; Ihara, T; Ito, M; Kamiya, H; Kitamura, K; Sakurai, M | 1 |
| Boiron, P; Freland, C; Fur, JL; Lelong, P; Nemirovsky-Trebucq, B | 1 |
| Das-Young, LR; Frank, E; Ramirez-Ronda, C; Schwartz, R | 1 |
| Cordonnier, C; Delain, M; Delmer, A; Gardembas, M; Gres, JJ; Herbrecht, R; Ladeb, S; Moreau, P; Nalet, V; Pico, JL; Rollin, C | 1 |
| Chen, DK; Chen, YF; Gu, JM; Hou, J; Hu, WZ; Jia, YX; Li, JT; Li, LJ; Liu, DM; Lu, Y; Miao, JZ; Sun, L; Wang, HL; Wang, Z; Wu, J; Zhang, XZ; Zhang, YL | 1 |
| Alekseev, AA; Blatun, LA; Iakovlev, VP; Izotova, GN; Krutikov, MG; Puchkova, LS; Svetukhin, AM | 1 |
| Amodio-Groton, M; Epstein, ME; Sadick, NS | 1 |
| Fujiyama, S; Tanaka, M | 1 |
| Darmstadt, GL | 1 |
| Bhutta, ZA; Ladhani, S | 1 |
| Akiyama, H; Arata, J; Kanzaki, H; Tada, J; Yamasaki, O | 1 |
| Asumang, A; Dryden, M; Goldsmith, AL | 1 |
| Azimi, PH; Barson, WJ; Janner, D; Swanson, R | 1 |
| Barriere, SL; Dunn, DL; Graham, DR; Kreter, B; Nichols, RL; Rodgers, A; Wilson, SE; Zervos, M | 1 |
| Kaya, O; Kirkan, S; Unal, B | 1 |
| Church, D; Fidelholtz, J; Haverstock, D; Heyd, A; Miskin, B; Parish, LC; Routh, HB; Werschler, P | 1 |
| Aragane, Y; Asai, M; Kawada, A; Maeda, A; Shiraishi, H; Tezuka, T | 1 |
| SoRelle, R | 1 |
| Thompson, CA | 1 |
| Bushnell, WD; Capin, LR; Cupo, MA; Parish, LC; Rist, T; Sulica, V | 1 |
29 review(s) available for cephalosporin c and Skin Diseases, Bacterial
| Article | Year |
|---|---|
Possible clinical indications of ceftobiprole.
Topics: Anti-Bacterial Agents; Bacterial Infections; Catheter-Related Infections; Cephalosporins; Cross Infection; Diabetic Foot; Fever of Unknown Origin; Humans; Inpatients; Pneumonia, Bacterial; Skin Diseases, Bacterial; Soft Tissue Infections | 2019 |
Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections.
Topics: Acute Disease; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Approval; Drug Design; Drug Interactions; Humans; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Staphylococcal Infections; United States; United States Food and Drug Administration | 2014 |
What's new in the treatment of serious MRSA infection?
Topics: Acetamides; Anti-Bacterial Agents; Cephalosporins; Cost-Benefit Analysis; Drug Administration Routes; Drug Therapy, Combination; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxazolidinones; Severity of Illness Index; Skin Diseases, Bacterial; Staphylococcal Infections; Tetrazoles; Vancomycin | 2014 |
Systematic Review and Meta-Analysis To Estimate Antibacterial Treatment Effect in Acute Bacterial Skin and Skin Structure Infection.
Topics: Adolescent; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Linezolid; Randomized Controlled Trials as Topic; Skin; Skin Diseases, Bacterial | 2015 |
Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA.
Topics: Anti-Bacterial Agents; Bayes Theorem; Ceftaroline; Cephalosporins; Daptomycin; Humans; Linezolid; Methicillin-Resistant Staphylococcus aureus; Organophosphates; Oxazoles; Oxazolidinones; Skin Diseases, Bacterial; Staphylococcal Infections; Tetrazoles; Vancomycin | 2017 |
Ceftaroline: a cephalosporin with expanded Gram-positive activity.
Topics: Adult; Animals; Ceftaroline; Cephalosporins; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Mice; Skin Diseases, Bacterial; Treatment Outcome | 2009 |
Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
Topics: Anti-Bacterial Agents; Bacteria; Cephalosporins; Clinical Trials as Topic; Drug Resistance, Bacterial; Europe; Humans; Latin America; Microbial Sensitivity Tests; North America; Respiratory Tract Infections; Skin Diseases, Bacterial | 2009 |
Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase III as Topic; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Multicenter Studies as Topic; Skin Diseases, Bacterial; Treatment Outcome | 2009 |
Meta-analysis of a possible signal of increased mortality associated with cefepime use.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Cefepime; Cephalosporins; Child; Child, Preschool; Clinical Trials as Topic; Female; Fever of Unknown Origin; Humans; Infant; Infant, Newborn; Male; Middle Aged; Neutropenia; Pneumonia, Bacterial; Skin Diseases, Bacterial; Survival Analysis; Urinary Tract Infections; Young Adult | 2010 |
Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials, Phase III as Topic; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Skin Diseases, Bacterial; Soft Tissue Infections; Treatment Outcome | 2010 |
Ceftaroline: a comprehensive update.
Topics: Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Drug Approval; Humans; Pneumonia, Bacterial; Prodrugs; Skin Diseases, Bacterial; Soft Tissue Infections; United States | 2011 |
Ceftaroline fosamil: a new broad-spectrum cephalosporin.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Pneumonia, Bacterial; Prodrugs; Skin Diseases, Bacterial; Soft Tissue Infections; United States | 2011 |
Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Topics: Animals; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Drug Evaluation, Preclinical; Humans; Methicillin-Resistant Staphylococcus aureus; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Staphylococcal Infections | 2011 |
MRSA new treatments on the horizon: current status.
Topics: Aminoglycosides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Glycopeptides; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Teicoplanin | 2011 |
[Ceftaroline fosamil, a broad spectrum cephalosporin antibiotic for the treatment of community-acquired pneumonia and complicated skin and skin structure infections].
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Pneumonia, Bacterial; Skin Diseases, Bacterial | 2011 |
Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Pneumonia, Bacterial; Skin Diseases, Bacterial | 2012 |
Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Double-Blind Method; Humans; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial | 2012 |
Cefditoren, a new aminothiazolyl cephalosporin.
Topics: Acute Disease; Bacterial Infections; Bronchitis, Chronic; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Drug Interactions; Humans; Maxillary Sinusitis; Pharyngitis; Pneumonia, Bacterial; Skin Diseases, Bacterial | 2002 |
Overview of cefdinir: pharmacokinetics, safety, and efficacy in the treatment of uncomplicated skin and skin structure infections.
Topics: Adult; Anti-Infective Agents; Cefdinir; Cephalosporins; Child; Humans; Skin Diseases, Bacterial; Soft Tissue Infections | 2004 |
Therapeutic experience with cefdinir in the treatment of uSSSIs.
Topics: Adult; Anti-Bacterial Agents; Cefdinir; Cephalosporins; Child; Female; Humans; Male; Skin Diseases, Bacterial | 2006 |
Cephalosporins for uncomplicated skin and skin structure infections in emerging community-acquired MRSA.
Topics: Adult; Cephalosporins; Child; Community-Acquired Infections; Humans; Methicillin Resistance; Skin Diseases, Bacterial; Staphylococcal Skin Infections | 2006 |
Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.
Topics: Anti-Bacterial Agents; Cephalosporins; Clinical Trials as Topic; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Skin Diseases, Bacterial; Staphylococcal Infections; Staphylococcal Skin Infections | 2007 |
Pharmacokinetic and pharmacodynamic profile of ceftobiprole.
Topics: Anti-Bacterial Agents; Cephalosporins; Cross Infection; Humans; Monte Carlo Method; Pneumonia; Skin Diseases, Bacterial | 2008 |
The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials.
Topics: Cephalosporins; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Skin Diseases, Bacterial; Treatment Outcome | 2008 |
Comparative studies of cefprozil in the management of skin and soft-tissue infections.
Topics: Adolescent; Adult; Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Infections; Cefaclor; Cefprozil; Cephalosporins; Child; Child, Preschool; Clavulanic Acids; Clinical Trials as Topic; Drug Therapy, Combination; Erythromycin; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Skin Diseases, Bacterial; Soft Tissue Infections | 1994 |
Primary cutaneous nocardiosis caused by Nocardia otitidiscaviarum: two cases and a review of the literature.
Topics: Abscess; Adult; Anti-Bacterial Agents; Cephalexin; Cephalosporins; Female; France; Gentamicins; Humans; Male; Middle Aged; Minocycline; Mycetoma; Nocardia; Nocardia Infections; Skin Diseases, Bacterial; Travel; Vietnam; Zimbabwe | 1995 |
Antimicrobial agents for the dermatologist. I. Beta-lactam antibiotics and related compounds.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Combinations; Humans; Monobactams; Skin Diseases, Bacterial | 1997 |
[Vibrio vulnificus infections].
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Risk Factors; Seasons; Sepsis; Skin Diseases, Bacterial; Tetracyclines; Vibrio; Vibrio Infections | 1998 |
Antibiotics in the management of pediatric skin disease.
Topics: 4-Quinolones; Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Child; Drug Resistance, Microbial; Humans; Infant; Macrolides; Penicillins; Skin Diseases, Bacterial; Staphylococcus aureus; Tetracyclines | 1998 |
23 trial(s) available for cephalosporin c and Skin Diseases, Bacterial
| Article | Year |
|---|---|
Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Double-Blind Method; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2021 |
Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Female; Humans; Infusions, Intravenous; Injections, Intramuscular; Male; Middle Aged; Models, Biological; Pneumonia, Bacterial; Skin Diseases, Bacterial; Young Adult | 2013 |
A Multicenter, Randomized, Observer-blinded, Active-controlled Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infection.
Topics: Acute Disease; Adolescent; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Child; Child, Preschool; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Skin Diseases, Bacterial; Staphylococcus aureus; Streptococcus pyogenes; Treatment Outcome | 2016 |
A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Prospective Studies; Skin Diseases, Bacterial; Soft Tissue Infections; Systemic Inflammatory Response Syndrome; Treatment Outcome; Vancomycin; Young Adult | 2016 |
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Skin Diseases, Bacterial; Staphylococcus | 2008 |
Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin; Young Adult | 2010 |
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Humans; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Treatment Outcome; Vancomycin; Young Adult | 2010 |
CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Humans; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Treatment Outcome; Vancomycin; Young Adult | 2010 |
Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Double-Blind Method; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Treatment Outcome; Vancomycin | 2010 |
CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Biomarkers; Ceftaroline; Cephalosporins; Drug Administration Schedule; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Injections, Intravenous; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Retrospective Studies; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2012 |
TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Double-Blind Method; Drug Administration Schedule; Female; Glycopeptides; Humans; Injections, Intravenous; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Skin; Skin Diseases, Bacterial; Staphylococcal Infections; Vancomycin | 2012 |
Cefdinir vs. cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults.
Topics: Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Cefdinir; Cellulitis; Cephalexin; Cephalosporins; Female; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Middle Aged; Skin Diseases, Bacterial; Staphylococcus aureus; Staphylococcus epidermidis; Wound Infection | 2006 |
Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Double-Blind Method; Female; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Male; Middle Aged; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2008 |
A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
Topics: Aged; Ceftazidime; Cephalosporins; Double-Blind Method; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2008 |
The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials.
Topics: Cephalosporins; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Skin Diseases, Bacterial; Treatment Outcome | 2008 |
Current and future management of serious skin and skin-structure infections.
Topics: Bacteria; Cefepime; Ceftazidime; Cephalosporins; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Skin Diseases; Skin Diseases, Bacterial | 1996 |
Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Bacterial Infections; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Fever; Gastrointestinal Diseases; Gram-Negative Bacteria; Gram-Positive Bacteria; Hematologic Neoplasms; Humans; Male; Neutropenia; Skin Diseases, Bacterial; Soft Tissue Infections; Urinary Tract Infections | 1997 |
Sulbactam/cefoperazone versus cefotaxime for the treatment of moderate-to-severe bacterial infections: results of a randomized, controlled clinical trial.
Topics: Adolescent; Adult; Aged; Bacteria; Bacterial Infections; beta-Lactamase Inhibitors; Cefoperazone; Cefotaxime; Cephalosporins; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Respiratory Tract Infections; Skin Diseases, Bacterial; Sulbactam; Urinary Tract Infections | 1997 |
[Use of cefpirome in the treatment of patients with skin and soft tissue infections].
Topics: Adolescent; Adult; Burns; Cefpirome; Cephalosporins; Humans; Microbial Sensitivity Tests; Middle Aged; Necrosis; Skin Diseases, Bacterial; Soft Tissue Infections; Treatment Outcome; Wound Infection | 1996 |
Efficacy and safety of ampicillin/sulbactam and cefuroxime in the treatment of serious skin and skin structure infections in pediatric patients. UNASYN Pediatric Study Group.
Topics: Ampicillin; Cefuroxime; Cephalosporins; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Infant; Male; Prospective Studies; Skin Diseases, Bacterial; Sulbactam; Treatment Outcome | 1999 |
Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Gr
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cefazolin; Cephalosporins; Female; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Hospitalization; Humans; Male; Middle Aged; Oxacillin; Penicillins; Skin Diseases, Bacterial; Vancomycin; Virginiamycin | 1999 |
Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anti-Infective Agents; Cephalexin; Cephalosporins; Chi-Square Distribution; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Streptococcal Infections; Therapeutic Equivalency; Treatment Outcome | 2000 |
A comparison of the efficacy and safety of mupirocin cream and cephalexin in the treatment of secondarily infected eczema.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Anti-Bacterial Agents; Cephalexin; Cephalosporins; Diarrhea; Double-Blind Method; Drug Administration Schedule; Eczema; Female; Humans; Male; Middle Aged; Mupirocin; Ointments; Opportunistic Infections; Patient Satisfaction; Skin Diseases, Bacterial | 2002 |
61 other study(ies) available for cephalosporin c and Skin Diseases, Bacterial
| Article | Year |
|---|---|
Multicenter Study of the Real-World Use of Ceftaroline versus Vancomycin for Acute Bacterial Skin and Skin Structure Infections.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Female; Humans; Male; Middle Aged; Retrospective Studies; Skin; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin | 2019 |
Antimicrobial activity of ceftolozane/tazobactam tested against contemporary (2015-2017) Pseudomonas aeruginosa isolates from a global surveillance programme.
Topics: Asia; Cephalosporins; Europe; Female; Global Health; Humans; Latin America; Male; Microbial Sensitivity Tests; North America; Pacific Islands; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Public Health Surveillance; Sepsis; Skin Diseases, Bacterial; Tazobactam | 2020 |
Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Humans; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2020 |
Susceptibility of clinical isolates of meticillin-resistant Staphylococcus aureus and phenotypic non-extended-spectrum β-lactamase-producing Klebsiella pneumoniae to ceftaroline in Taiwan: Results from Antimicrobial Testing Leadership and Surveillance (AT
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Humans; Klebsiella pneumoniae; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Respiratory Tract Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Taiwan | 2020 |
Efficacy and safety of ceftobiprole in patients aged 65 years or older: a
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Pneumonia; Skin Diseases, Bacterial; Treatment Outcome | 2021 |
Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
Topics: Adolescent; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Child; Child, Preschool; Community-Acquired Infections; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Haemophilus influenzae; Hospitals; Humans; Infant; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Respiratory Tract Infections; Retrospective Studies; Skin Diseases, Bacterial; Staphylococcal Infections; Streptococcus pneumoniae; United States | 2017 |
Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam.
Topics: Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2017 |
Antimicrobial activities of LCB10-0200, a novel siderophore cephalosporin, against the clinical isolates of Pseudomonas aeruginosa and other pathogens.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Disease Models, Animal; Female; Humans; Male; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Sepsis; Siderophores; Skin Diseases, Bacterial; Treatment Outcome; Urinary Tract Infections | 2017 |
Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Osteomyelitis; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam; Treatment Outcome | 2018 |
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Bone Diseases, Infectious; Cephalosporins; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Skin Diseases, Bacterial; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2019 |
Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Clinical Trials, Phase III as Topic; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Skin Diseases, Bacterial; Systemic Inflammatory Response Syndrome; Treatment Outcome | 2019 |
Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010).
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Escherichia coli; Europe; Gram-Positive Cocci; Humans; Klebsiella; Microbial Sensitivity Tests; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Skin Infections | 2013 |
Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
Topics: Anti-Bacterial Agents; Asia; Ceftaroline; Cephalosporins; Community-Acquired Infections; Haemophilus influenzae; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moraxella catarrhalis; Respiratory Tract Infections; Skin Diseases, Bacterial; Soft Tissue Infections; South Africa; Staphylococcus aureus; Streptococcus pneumoniae | 2013 |
Ceftaroline fosamil use in hospitalized patients with acute bacterial skin and skin structure infections: Budget impact analysis from a hospital perspective.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Costs and Cost Analysis; Drug Therapy, Combination; Economics, Hospital; Formularies, Hospital as Topic; Humans; Length of Stay; Models, Economic; Skin Diseases, Bacterial; Vancomycin | 2013 |
Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ceftaroline; Cephalosporins; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Retrospective Studies; Skin; Skin Diseases, Bacterial; Skin Diseases, Infectious; Staphylococcal Infections; Young Adult | 2013 |
Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
Topics: Academic Medical Centers; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Skin Diseases, Bacterial; Soft Tissue Infections; United States | 2014 |
Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012).
Topics: Academic Medical Centers; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteria; Ceftaroline; Cephalosporins; Humans; Microbial Sensitivity Tests; Skin Diseases, Bacterial; United States | 2014 |
Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.
Topics: Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Retrospective Studies; Skin Diseases, Bacterial | 2014 |
[Case of the abscess type cutaneous nocardiosis].
Topics: Abscess; Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Drug Therapy, Combination; Female; Gentamicins; Humans; Middle Aged; Nocardia; Nocardia Infections; Skin Diseases, Bacterial; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2014 |
[Role of ceftaroline in skin and soft tissue infections].
Topics: Ceftaroline; Cephalosporins; Humans; Skin Diseases, Bacterial; Soft Tissue Infections | 2014 |
Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
Topics: Adolescent; Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Child; Child, Preschool; Drug Resistance, Bacterial; Humans; Infant; Infant, Newborn; Microbial Sensitivity Tests; Serotyping; Skin Diseases, Bacterial; Soft Tissue Infections | 2014 |
Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in elderly patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Drug Therapy, Combination; Drug Utilization; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Retrospective Studies; Skin Diseases, Bacterial | 2014 |
Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections in obese patients.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Female; Humans; Length of Stay; Male; Middle Aged; Obesity; Patient Discharge; Retrospective Studies; Sex Factors; Skin Diseases, Bacterial; Socioeconomic Factors; United States; Young Adult | 2014 |
[Efficacy of ceftaroline in treating complicated skin and soft tissue infections].
Topics: Aztreonam; Ceftaroline; Cephalosporins; Drug Therapy, Combination; Humans; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Soft Tissue Infections; Vancomycin | 2014 |
[Therapy of skin and soft tissue infections from surgeon's point of view].
Topics: Algorithms; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Opportunistic Infections; Postoperative Care; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections | 2014 |
Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Pneumonia; Renal Insufficiency; Retrospective Studies; Skin Diseases, Bacterial; Young Adult | 2015 |
Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Europe; Humans; Infusions, Intravenous; Kidney; Kidney Function Tests; Monte Carlo Method; Pneumonia, Bacterial; Skin Diseases, Bacterial; Treatment Outcome | 2015 |
Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013.
Topics: Academic Medical Centers; Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Microbial Sensitivity Tests; Respiratory Tract Infections; Skin Diseases, Bacterial; United States | 2015 |
Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).
Topics: Adult; Aged; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Registries; Retrospective Studies; Skin Diseases, Bacterial | 2016 |
In vitro bactericidal activity of cefepime and cefpirome against clinical isolates at Karachi.
Topics: Anti-Bacterial Agents; Bacteremia; Cefepime; Cefpirome; Cephalosporins; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; In Vitro Techniques; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Pakistan; Proteus; Proteus Infections; Respiratory Tract Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Staphylococcus aureus; Urinary Tract Infections | 2015 |
Pathogens of skin and skin-structure infections in the UK and their susceptibility to antibiotics, including ceftaroline.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Skin Diseases, Bacterial; United Kingdom; Young Adult | 2015 |
In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme.
Topics: Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Drug Resistance, Bacterial; Epidemiological Monitoring; Europe; Humans; Microbial Sensitivity Tests; Prevalence; Skin Diseases, Bacterial; Soft Tissue Infections; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2016 |
Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Skin Diseases, Bacterial; Staphylococcal Infections; Staphylococcus aureus | 2016 |
In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012-2014.
Topics: Africa; Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; Epidemiological Monitoring; Humans; Microbial Sensitivity Tests; Middle East; Respiratory Tract Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2016 |
Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.
Topics: Acute Disease; Adolescent; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Child; Child, Preschool; Clinical Trials as Topic; Community-Acquired Infections; Computer Simulation; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Models, Biological; Pneumonia, Bacterial; Skin Diseases, Bacterial; Staphylococcus aureus; Streptococcus pneumoniae | 2017 |
Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane/tazobactam.
Topics: Anti-Infective Agents, Urinary; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Male; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Skin Diseases, Bacterial; Soft Tissue Infections; Tazobactam | 2017 |
[Bacteriology of cutaneous infections of the child].
Topics: Bacterial Proteins; beta-Lactam Resistance; beta-Lactams; Cephalosporins; Child; Drug Resistance, Bacterial; Humans; Macrolides; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Methyltransferases; Penicillin G; Penicillin Resistance; Penicillins; Risk Factors; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes | 2008 |
[Managing children skin and soft tissue infections].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Cellulitis; Cephalosporins; Child; Drug Resistance, Bacterial; Fasciitis, Necrotizing; Furunculosis; Fusidic Acid; Humans; Impetigo; Injections, Intravenous; Macrolides; Methicillin-Resistant Staphylococcus aureus; Mupirocin; Penicillins; Pristinamycin; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Scalded Skin Syndrome; Staphylococcal Skin Infections; Staphylococcus aureus; Stevens-Johnson Syndrome; Streptococcal Infections; Streptococcus pyogenes | 2008 |
Antimicrobial development in the era of emerging resistance.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Bacteria; beta-Lactams; Cephalosporins; Drug Approval; Drug Resistance, Bacterial; Glycopeptides; Humans; Lipoglycopeptides; Pyrimidines; Skin Diseases, Bacterial; Skin Diseases, Viral; Teicoplanin; United States; United States Food and Drug Administration | 2009 |
Ceftaroline for complicated skin and skin-structure infections.
Topics: Animals; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Staphylococcal Infections | 2010 |
Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials, Phase III as Topic; Europe; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Population Surveillance; Skin Diseases, Bacterial; Soft Tissue Infections; Treatment Outcome; United States | 2010 |
The problem of complicated skin and skin structure infections: the need for new agents.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials, Phase III as Topic; Drug Resistance, Bacterial; Humans; Methicillin-Resistant Staphylococcus aureus; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Skin Infections | 2010 |
Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Half-Life; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections | 2010 |
Ceftaroline fosamil: drug profile and clinical data.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Ceftaroline; Cephalosporins; Clinical Trials as Topic; Community-Acquired Infections; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Mice; Microbial Sensitivity Tests; Pneumonia, Bacterial; Rabbits; Skin Diseases, Bacterial | 2011 |
Pharmacokinetics of Cefovecin in squirrel monkey (Saimiri sciureus), rhesus macaques (Macaca mulatta), and cynomolgus macaques (Macaca fascicularis).
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Cephalosporins; Dog Diseases; Dogs; Half-Life; Injections, Subcutaneous; Macaca fascicularis; Macaca mulatta; Male; Saimiri; Skin Diseases, Bacterial; Species Specificity | 2010 |
Ceftaroline fosamil (Teflaro) - a new IV cephalosporin.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Infusions, Intravenous; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Skin Diseases, Bacterial; Staphylococcal Infections | 2011 |
Is cefepime safe for clinical use? A Bayesian viewpoint.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cefepime; Cephalosporins; Fever of Unknown Origin; Humans; Incidence; Neutropenia; Skin Diseases, Bacterial; Statistics as Topic; United States | 2011 |
Ceftaroline (Teflaro): a new cephalosporin.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Methicillin Resistance; Pneumonia, Bacterial; Skin Diseases, Bacterial; Staphylococcal Infections | 2011 |
Early endpoints for acute bacterial skin and skin structure infections.
Topics: Aztreonam; Biomarkers; Ceftaroline; Cephalosporins; Female; Humans; Male; Skin Diseases, Bacterial; Vancomycin | 2012 |
In vitro activity of ceftaroline and comparator antimicrobials against European and Middle East isolates from complicated skin and skin-structure infections collected in 2008-2009.
Topics: Anti-Bacterial Agents; Bacteria; Ceftaroline; Cephalosporins; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Europe; Genotype; Humans; Microbial Sensitivity Tests; Middle East; Multilocus Sequence Typing; Skin Diseases, Bacterial | 2012 |
Cutaneous abscess leading to sepsis by Aeromonas hydrophila.
Topics: Abscess; Aeromonas hydrophila; Cefepime; Cephalosporins; Ciprofloxacin; Fever; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Sepsis; Skin Diseases, Bacterial; Young Adult | 2013 |
Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolates.
Topics: Anti-Infective Agents; Bacteria; Cefdinir; Cephalosporins; Drug Resistance, Bacterial; Escherichia coli; Gram-Positive Cocci; Humans; Klebsiella; Microbial Sensitivity Tests; North America; Skin Diseases, Bacterial; Soft Tissue Infections | 2004 |
Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: are we evaluating the orally administered cephalosporins correctly?
Topics: Administration, Oral; Anti-Infective Agents; Cefdinir; Cephalosporins; Drug Resistance, Bacterial; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Skin Diseases, Bacterial; Soft Tissue Infections | 2006 |
[Clinical evaluation of S-1108 in children].
Topics: Adolescent; Bacteria; Bacterial Infections; Cephalosporins; Child; Child, Preschool; Drug Evaluation; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Respiratory Tract Infections; Skin Diseases, Bacterial; Urinary Tract Infections | 1993 |
Neonatal Pseudomonas putida infection presenting as staphylococcal scalded skin syndrome.
Topics: Ceftazidime; Cephalosporins; Diagnosis, Differential; Fatal Outcome; Humans; Infant, Newborn; Male; Pseudomonas Infections; Pseudomonas putida; Skin Diseases, Bacterial; Staphylococcal Scalded Skin Syndrome | 1998 |
Streptococci isolated from various skin lesions: the interaction with Staphylococcus aureus strains.
Topics: Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Erythromycin; Fluoroquinolones; Fusidic Acid; Humans; Imipenem; Microbial Sensitivity Tests; Minocycline; Naphthyridines; Ofloxacin; Penicillins; Skin Diseases, Bacterial; Species Specificity; Streptococcal Infections; Streptococcus; Vancomycin | 1999 |
Subcutaneous nodules with pseudomonas septicaemia in an immunocompetent patient.
Topics: Adult; Ceftazidime; Cephalosporins; Community-Acquired Infections; Female; Gentamicins; Humans; Immunocompetence; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Skin Diseases, Bacterial | 1999 |
Isolation of Dermatophilus congolensis from a cat.
Topics: Actinomycetales; Actinomycetales Infections; Amoxicillin; Ampicillin; Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Cefoperazone; Cephalosporins; Dermatitis; Gentamicins; Oxytetracycline; Penicillins; Rabbits; Skin Diseases, Bacterial; Streptomycin | 2000 |
Drug eruption induced by cefcapene pivoxil hydrochloride.
Topics: Cephalosporins; Diagnosis, Differential; Drug Eruptions; Female; Humans; Middle Aged; Patch Tests; Skin Diseases, Bacterial | 2001 |
Attempts to stem Anthrax fears stumble.
Topics: Adrenal Cortex Hormones; Anthrax; Bacillus anthracis; Bioterrorism; Centers for Disease Control and Prevention, U.S.; Cephalosporins; Ciprofloxacin; Contraindications; Doxycycline; Drug Therapy, Combination; Humans; Occupational Exposure; Penicillins; Postal Service; Respiratory Tract Infections; Skin Diseases, Bacterial; Spores, Bacterial; Trimethoprim, Sulfamethoxazole Drug Combination; United States | 2001 |
Oral prodrug enters cephalosporin market.
Topics: Administration, Oral; Bacterial Infections; Bronchitis; Cephalosporins; Drug Approval; Drug Interactions; Humans; Pharyngitis; Prodrugs; Skin Diseases, Bacterial; United States; United States Food and Drug Administration | 2001 |